S. Shiao

Taselisib (GDC-0032), a Potent β-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PIK3CA Alterations

J. Baselga, G. Gupta, C. Chung, 2015, Clinical Cancer Research.

Quantitative lymph node burden as a ‘very-high-risk’ factor identifying head and neck cancer patients benefiting from postoperative chemoradiation

M. Luu, A. Ho, Z. Zumsteg, 2019, Annals of Oncology.

Taselisib (GDC-0032), a Potent β-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PIK3CA Alterations

J. Baselga, G. Gupta, C. Chung, 2015, Clinical Cancer Research.